| abstract |
Histone deacetylases inhibitors (HDACIs) such as a compound having a structural formula of Cap-L-M wherein Cap-L-M is , and wherein is described herein and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed. |